(UroToday.com) The 2024 ESMO annual meeting included a highlights session, featuring a presentation by Dr. Ignacio Duran discussing highlights of the ESMO 2024 non-prostate cancer sessions. Dr. Duran started by highlighting the outline of his presentation discussing the most relevant presentations in kidney cancer and bladder cancer:
(UroToday.com) The 2024 ESMO annual meeting included a highlights session, featuring a presentation by Dr. Ursula Vogl discussing highlights of the ESMO 2024 prostate cancer sessions. The outline of prostate cancer highlights to guide Dr. Vogl’s discussion is summarized in the following figure:
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a proffered paper session for non-prostate genitourinary malignancies. Dr. Jørgen Bjerggaard Jensen presented the preliminary results from the TOMBOLA trial, which evaluated whether serial circulating tumour DNA (ctDNA) testing could be used to identify bladder cancer patients that could benefit from early post-cystectomy immunotherapy.
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a session focusing on rare genitourinary cancers. Dr. Angelika Terbuch discussed current controversies in testis cancer, focusing on the following topics:
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a proffered paper session for non-prostate genitourinary malignancies. Professor Andrea Necchi presented the results of an interim analysis of SunRISe-4, a randomized phase II trial of TAR-200 plus cetrelimab versus cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy.
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a proffered paper session for non-prostate genitourinary malignancies. Dr. Bogdana Schmidt delivered the discussant session for JCOG1019, TOMBALA, and SunRISe-4.
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the Proffered Paper session 2: GU, non-prostate. Dr. Shilpa Gupta discussed the presentations from Drs Andromachi Kougioumtzopoulou and Jens Bedke.
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a session focusing on rare genitourinary cancers. Professor Syed Hussain provided an overview of the histologic subtypes (i.e., variants) of bladder cancer.
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a proffered paper session for non-prostate genitourinary malignancies. Dr. Hiroshi Kitamura presented the results of JCOG1019, an open-label, non-inferiority, randomized phase III trial comparing the effectiveness of watchful waiting and intravesical Bacillus Calmette-Guérin (BCG) in patients with high-grade T1 bladder cancer with evidence of pT0 disease on the repeat transurethral resection specimen.
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 17th was host to the Proffered Paper session 2: GU, non-prostate. Dr. Andromachi Kougioumtzopoulou presented the findings of a a phase II, randomized study by the Hellenic GU Cancer Group exploring Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer, not undergoing cystectomy.
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 17th was host to the Proffered Paper session 2: GU, non-prostate. Dr. Jens Bedke presented the results of an exploratory analysis of the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma, exploring health-related quality of life.
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 17th was host to the presentation of Poster 1618. Dr. Anis Hamid discussed the clinical prognostic factors within the high-volume subgroup of metastatic hormone-sensitive prostate cancer (mHSPC) in the ENZAMET (ANZUP 1304) study.
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 17th was host to the session presentation of Poster 2016. Dr. Cora N. Sternberg discussed the evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant therapy.
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 17th was host to the presentation of the trial in progress 1662. Dr. Qian Qin presented HARMONY: A phase II study of niraparib/abiraterone acetate plus prednisone for Hispanic/Latino and non-Hispanic Black patients with metastatic hormone-sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa).
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of the poster 1615. Dr. Susan Halabi presented a new prognostic model of overall survival in patients with metastatic hormone sensitive prostate cancer (mHSPC).
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of Poster 1701. Dr. Liangyou Gu presented the results of NEOTAX: a Phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava (IVC) tumor thrombus.
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a genitourinary cancers poster session. Dr. Hedyeh Ebrahimi presented the results of a real-world study evaluating the characteristics and outcomes of patients with muscle-invasive urothelial carcinoma (MIUC) receiving nivolumab +/- neoadjuvant chemotherapy.
(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13th and 16th, 2024 was host to a genitourinary cancers poster session. Dr. Aleksander Antoniewicz presented the results of an interim analysis of a phase I study evaluating trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC).
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of Poster 2013. Dr. Gregor Duwe presented the first preliminary results of artificial intelligence (AI) generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project.
(UroToday.com) The 2024 European Society of Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain was host to the presentation of poster 1611. Dr. Kim Chi discussed the hematologic impact of [177Lu]Lu-PSMA-617 versus androgen receptor pathway inhibitor (ARPI) change in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PSMAfore trial.
